Brief: Nuvation Bio Doses First Patient In Phase 1B Combination Study Of Nuv-868
19/12/2022 21:07
Dec 19 (Reuters) - Nuvation Bio Inc NUVB.N :
* NUVATION BIO DOSES FIRST PATIENT IN PHASE 1B COMBINATION
STUDY
OF NUV-868
Source text for Eikon: ID:nBw9Wk2wga
Further company coverage: NUVB.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth